Company profile: Greer Laboratories
1.1 - Company Overview
Company description
- Provider of subcutaneous immunotherapy and allergenic extracts for allergy diagnosis and treatment, including non-standardized extracts; short ragweed pollen and short/giant ragweed pollen mix extracts; standardized cat hair extracts for asthma, rhinitis, and conjunctivitis; and standardized grass pollen extracts for skin test diagnosis and immunotherapy to reduce allergic symptoms.
Products and services
- Standardized Grass Pollen Allergenic Extracts: Extracts used for skin test diagnosis and immunotherapy to reduce allergic symptoms caused by various grass pollens, offered as standardized preparations
- Standardized Cat Hair Allergenic Extract: Extract used for skin test diagnosis and treatment of cat hair-induced allergic asthma, rhinitis, and conjunctivitis, offered as a standardized extract
- Subcutaneous Immunotherapy Treatment: A subcutaneous treatment gradually increases allergen doses to help the immune system develop resistance and reduce allergic symptoms over time
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Greer Laboratories
Aditxt
HQ: United States
Website
- Description: Provider of biotechnology solutions using novel nucleic acid-based technologies, including AditxtScore for personalized immune profiling; Apoptotic DNA Immunotherapy (ADI) to induce immune tolerance for transplants, autoimmune diseases, and allergies; Adimune for restoring immune tolerance; Pearsanta for personalized diagnostic and monitoring services; and Adivir developing medicines, diagnostics, and vaccines for public health threats.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aditxt company profile →
Resolvyx
HQ: United States
Website
- Description: Provider of therapeutics based on small molecule lipid mediators for the treatment of inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Resolvyx company profile →
Electra Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage monoclonal antibody therapies targeting SIRP proteins for cancer and immunological diseases. Lead candidate ELA026 is in clinical development for sHLH and preclinical for other inflammatory diseases, designed to deplete myeloid and T cells driving hyperinflammation. Additional SIRP-directed antibodies aim to deplete specific immune or tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Electra Therapeutics company profile →
NapaJen
HQ: United States
Website
- Description: Provider of oligonucleotide therapeutics and delivery technologies, offering NJA-730 for preventing acute immune diseases tied to bone marrow transplants; Napa9-SPG, a TLR9 agonist in preclinical immuno-oncology and vaccine adjuvant use; and a proprietary platform delivering nucleic acid drugs to immune cells. Provides partnerships for oligonucleotide development and NJA-730 licensing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NapaJen company profile →
Aclaris Therapeutics
HQ: United States
Website
- Description: Provider of dermatologic and immuno-inflammatory therapies R&D, using its KINect platform to discover small-molecule kinase inhibitors; conducts clinical trials; offers drug discovery and early development via Confluence Discovery Technologies; advancing ATI-1777 (topical JAK1/JAK3), ATI-2138 (oral ITK/JAK3), and Zunsemetinib/ATI-450 (oral MK2) for metastatic breast cancer and pancreatic ductal adenocarcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aclaris Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Greer Laboratories
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Greer Laboratories
2.2 - Growth funds investing in similar companies to Greer Laboratories
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Greer Laboratories
4.2 - Public trading comparable groups for Greer Laboratories
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →